Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michele Di Lorenzo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Longitudinal Multimodal Assessment of Pulmonary Nodules in Fibrosing Interstitial Lung Diseases: A Retrospective Study

    by Tommaso Pianigiani, Paolo Cameli, Michele Di Lorenzo, Laura Bergantini, Elena Bargagli

    Background Pulmonary nodules are increasingly detected during high-resolution computed tomography (HRCT) surveillance in patients with fibrosing interstitial lung diseases (fILD). However, nodule risk stratification is challenging in fibrotic lungs, and evidence guiding clinical management remains limited. We aimed to characterize the longitudinal behaviour of HRCT-detected nodules in fILD and identify predictors of malignancy. Methods We conducted a retrospective observational study at a tertiary ILD referral centre. All HRCT examinations performed between January 2018 and January 2022 in patients with multidisciplinary-diagnosed fILD were reviewed. Nodules (≤ 30 mm) were classified as low- or high-risk according to the 2017 Fleischner Society Guidelines. Nodules were adjudicated as malignant based on histopathology; benign nodules were defined by histological confirmation or long-term radiological stability (≥ 24 months). Clinical, functional, and radiological variables were analysed using univariate and multivariable logistic regression. Results Among 789 screened fILD patients, 91 (11.5%) had at least one pulmonary nodule, yielding 153 nodules (123 low-risk [80.4%] and 30 high-risk [19.6%]). Four patients were excluded due to incomplete diagnostic work-up, leaving 87 patients (mean age 73.3 ± 10.7 years; 71.3% male) with definitively characterized nodules. Thirteen patients were diagnosed with lung cancer (9 squamous cell carcinomas; 4 adenocarcinomas). All malignant nodules occurred in the high-risk group (13/30, 43.3%), whereas none of the low-risk nodules were malignant (p < 0.001). In univariate analysis, nodule size was significantly associated with malignancy (OR 1.18; 95% CI 1.07–1.29; p = 0.031). Among the variables assessed, nodule size was the only variable independently associated with malignancy in multivariable analysis (OR 1.17; 95% CI 1.01–1.35; p = 0.041). Smoking exposure, HRCT pattern (UIP vs. non-UIP), ILD subtype, pulmonary function parameters, antifibrotic therapy, morphology, number of nodules, symptoms, and radiological progression were not independently associated with malignancy. Conclusions In fILD, conventional nodule risk features may be less informative than in non-fibrotic lungs. Among the variables assessed, nodule size was the only variable independently associated with malignancy in multivariable analysis, supporting the need for ILD-specific strategies to optimize surveillance and avoid unnecessary invasive procedures. Clinical trial registration Clinical trial number: not applicable.


  • Open Access

    Genetic Profile of Pediatric-Onset Cardiac Channelopathies

    by Sara Giovani, Adelaide Ballerini, Alessia Gozzini, Michele Di Lorenzo, Davide Mei, Silvia Passantino, Mattia Zampieri, Alessia Tomberli, Alberto Marchi, Giovanni Battista Calabri, et al.

    This study investigates the genetic background of pediatric-onset cardiac channelopathies, a rare group of genetic disorders causing arrhythmias and sometimes sudden death, whose genetic background remains partially unknown. The research analyzed 59 pediatric patients (KCNQ1 (42%), RYR2 (16%), CACNA1C (10%), and SCN5A (10%) genes. Notably, a de novo large deletion in KCNH2 was detected in an LQTS patient, and a pathogenic CALM1 variant was identified in a child. A compound heterozygous KCNQ1 was consistent with Jervell and Lange-Nielsen syndrome. In light of these data, genetic testing is crucial for diagnosis, prognosis, and treatment planning; cascade screening allowed early risk identification and preventive interventions for family members. Expanding NGS technologies and research on new candidate genes may enhance personalized therapies in the future.